Atriva TherapeuticsTherapies against viral infections. More Info The Atriva Approach First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza. Great potential against a wide variety of respiratory viruses due to immunomodulating and antivira ...
Location: Germany, Baden-Württemberg, Tübingen
Total raised: $10.19M
Investors 2
| Date | Name | Website |
| - | Meneldor | meneldor.n... |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.08.2020 | - | $10.19M | - |
Mentions in press and media 11
| Date | Title | Description |
| 21.10.2022 | Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates | David Hollander → Revance feels like it has a competitive advantage over AbbVie’s blockbuster Botox with only biannual injections of its freshly approved Daxxify, as opposed to the injections every three or four months... |
| 25.03.2022 | Roger Perlmutter lures Roy Baynes away from Merck; Now, Voyager: Al Sandrock becomes a CEO after break from Biogen | Roy Baynes → Professional sports teams cycle through free agency every year, and core veterans from championship clubs routinely splinter off in different directions. In a similar vein, Merck in particular has seen widespread turnover with ... |
| 10.01.2022 | Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections | DGAP-News: Atriva Therapeutics GmbH / Key word(s): Regulatory Admission Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections 10.01.2022 / 14:30 The issuer is solely responsible for the content of this ... |
| 16.04.2021 | Novavax CFO Greg Covino makes a quick exit as leadership carousel keeps turning; Kite execs fly away to a cell therapy upstart teaming up with Lyell | Greg Covino → If it seems like Covid-19 vaccine bridesmaid Novavax is shuttling staffers in and out, you’re not alone. This week, Greg Covino announced he’s leaving the biotech after holding the CFO job for a blink-and-you-miss-it... |
| 13.04.2021 | Atriva Therapeutics GmbH : Announces Changes to Management | DGAP-News: Atriva Therapeutics GmbH / Key word(s): Personnel Atriva Therapeutics Announces Changes to Management 13.04.2021 / 09:30 The issuer is solely responsible for the content of this announcement. Atriva Therapeutics Announces Changes... |
| 19.08.2020 | Atriva Therapeutics Closes €8.6M Oversubscribed Convertible Loan | Atriva Therapeutics, a Tübingen and Frankfurt, Germany-based biopharmaceutical company developing host-targeting antiviral therapies, closed a € 8.6m ($ 10.2m) convertible loan. The round was led by Meneldor B.V. and High-Tech Gründerfonds ... |
| 11.01.2019 | Atriva Therapeutics Raises Initial Series A Funding | Atriva Therapeutics, a Tübingen, Germany-based biopharmaceutical company developing host-targeting antiviral therapies, held the first closing in its ongoing series A financing round. The round was led by Meneldor and High-Tech Gründerfonds... |
| 22.09.2017 | Atriva Receives Additional Tranche of Seed Financing | Atriva Therapeutics GmbH, a Tübingen, Germany-based developer of innovative antiviral therapies, raised an additional tranche of seed funding. The round, which now amounts to €3m in total funding, was co-led by Stichting Participatie Atriva... |
| 08.02.2017 | Atriva Raises Seed Funding Round | Atriva Therapeutics, a Tübingen, Germany-based developer of an innovative influenza therapeutic, raised a seed funding round of undisclosed amount. Backers included Dutch Stichting Participatie Atriva and German High-Tech Gründerfonds. The ... |
| - | HTGF portfolio company: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment | The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s dev... |
Show more